Background: There are increasing concerns about risks associated with aspirin
discontinuation in the absence of major surgery or bleeding. We investigated whether long …

Objectives To evaluate the risk of myocardial infarction and death from coronary heart
disease after discontinuation of low dose aspirin in primary care patients with a history of …

Background Low-dose aspirin has proven effectiveness in secondary and primary
prevention of cardiovascular events, but is also associated with an increased risk of major …

Long-term therapy with low-dose aspirin (acetylsalicylic acid; ASA), 75–325 mg, is highly
effective for the secondary prevention of cardiovascular (CV) events. For high-CV-risk …

OBJECTIVE: Many recommendations for aspirin in stable cardiovascular disease are based
on analyses of all antiplatelet therapies at all dosages and in both stable and unstable …

Background The appropriate dose of aspirin to lower the risk of death, myocardial infarction,
and stroke and to minimize major bleeding in patients with established atherosclerotic …

Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse
events in patients with coronary artery disease (CAD), use of the most widely available and …

Introduction The use of aspirin in patients without cardiovascular disease remains
controversial. Patients' understanding of the risks and benefits of aspirin likely contribute to …

Aims The role of aspirin in patients with coronary artery disease (CAD) is well established,
yet patients happen to discontinue aspirin according to physician's advice or unsupervised …

Background—The goal of the present study was to assess national trends and patterns of
aspirin use among outpatients with coronary artery disease. Although there is strong …